Catheter Precision Reports Stellar Third Quarter Results
Catheter Precision, Inc. (NYSE: VTAK), an innovative medical device company focusing on the cardiac electrophysiology marketplace, has reported impressive outcomes for the quarter and the first nine months of the fiscal year. The results indicate significant growth, demonstrating resilience and forward momentum within a competitive industry.
Financial Highlights for Q3 2025
In the third quarter of 2025, Catheter Precision recorded total revenue of $226,000, marking a remarkable increase of 135% compared to $96,000 during the same period in 2024. Furthermore, total revenue for the nine months ending September 30, 2025, reached $581,000, a 114% increase from $271,000 in the same timeframe last year.
Net Loss and Financial Performance
The net loss for Q3 2025 stood at $2,251,000, reflecting a 45% reduction from a net loss of $4,120,000 in Q3 2024. For the nine-month period, net losses were reported at $11,405,000 versus $11,015,000 in the previous year, showing a stabilization in financial health as Catheter Precision navigates its expansion strategy.
Commercial Progress and Market Expansion
Commercial activities for Catheter Precision's products are gaining momentum, particularly for the LockeT device outside of the United States. The product has received CE Mark approval, generating considerable interest in various international markets, including Germany, France, Italy, Spain, Portugal, the UK, and South Africa. In October, five accounts in South Africa re-ordered the LockeT device, signaling strong market demand.
Advances in VIVO Sales
Sales activities have also ramped up for the VIVO product line, which has seen additional accounts adopting its use, including a notable purchase order from France in October. This trend highlights Catheter Precision's focus on enhancing its international footprint.
Prioritizing Clinical Studies and Publication
Clinical studies remain a key priority for Catheter Precision. Recently, an interview with Dr. Luigi Di Biase, a leading figure in electrophysiology, was featured in a well-regarded publication. He underscored the economic advantages of the LockeT device for venous closure following electrophysiology procedures, further validating the company’s technical innovations.
CEO's Insights on Company Growth
David Jenkins, CEO of Catheter Precision, expressed optimism regarding the company's future, stating, "We believe we are entering a pivotal growth period. With our established pipeline and the anticipated outcome of our VIVO clinical studies in 2025, we aim to expand our market presence significantly and enhance treatment for patients experiencing ventricular arrhythmias."
About Catheter Precision
Catheter Precision is dedicated to advancing cardiac arrhythmia treatments with cutting-edge medical device technologies. By fostering collaborations with healthcare professionals, the company continuously enhances its product offerings, ensuring they meet the evolving needs of the medical community.
Overview of VIVO Technology
VIVO™ (View Into Ventricular Onset) is a groundbreaking non-invasive 3D imaging system developed by Catheter Precision. It allows physicians to determine the origins of ventricular arrhythmias before procedures, thus streamlining workflows and cutting down on procedure durations. The product has received FDA marketing clearance and holds a CE mark.
Understanding LockeT Device
LockeT is a suture retention device geared toward assisting in hemostasis after venous punctures. Designated as a Class 1 device with FDA registration, LockeT is also CE-marked, further attesting to its safety and efficacy in clinical settings.
Frequently Asked Questions
What are the financial highlights for Catheter Precision in Q3 2025?
In Q3 2025, total revenue reached $226,000, which is a 135% increase from the previous year. The net loss decreased to $2,251,000 from $4,120,000.
How is Catheter Precision expanding internationally?
The company has gained CE Mark approval for the LockeT device, leading to increased orders from various countries, including Germany and South Africa.
What technologies does Catheter Precision provide for cardiac treatment?
Catheter Precision focuses on innovative devices like the VIVO imaging system and the LockeT suture retention device, improving procedure outcomes in cardiac electrophysiology.
Who is the CEO of Catheter Precision?
David Jenkins serves as the CEO of Catheter Precision and has expressed confidence in the company’s growth strategy and product innovations.
What are the future prospects for Catheter Precision?
The company is optimistic about its potential for growth, particularly with upcoming clinical studies and planned expansions in both U.S. and international markets.
